Yeah. I'm surprised the nutso Canadian volume hasn't affected the US share volume, yet. People not paying attention, still, I guess. Or people are wary of illiquidity, maybe. (Catch-22, that.)
Of course, it might just be cheaper for IMNP to buy ICO (using Azria, the new chair of transactions) than to pay them milestones. Fun speculation.
IMNP's recent progress with Bertilimumab (ICO-008) bodes very very well for ICO. Any influx of cash from milestones, at these valuation levels, would be a huge shot in the arm for share price, as we've already seen with the IMNP announcement. I wish we had a bit more clarity about the structure of payments, but there is $32M to be had at various milestones reached by Immune. One would think initiation, completion, or approval of P2 and P3 would trigger a milestone. Some combination of these should happen this year, according to IMNP. This doesn't take into account increased value of IMNP shares, which will also contribute to ICO's value.